Neuropeptide Biomarker Differentiates Ischemic Stroke
|
By LabMedica International staff writers Posted on 21 Aug 2012 |
|
A biomarker of blood-brain barrier (BBB) disruption may distinguish an ischemic stroke from a transient ischemic attack (TIA) or an intracerebral hemorrhage, and may help to determine its severity.
Plasma concentrations of precursor fragments of the neuropeptide enkephalin (proenkephalin A, or PENK-A) are elevated in patients with acute stroke, and are correlated with stroke severity and with brain lesion size, and they predicted mortality and more severe functional disability.
Scientists at the Center for Stroke Research (Berlin, Germany) measured plasma PENK-A and protachykinin A (PTA) concentrations in 189 consecutive patients who were admitted to hospital with symptoms of acute stroke. Midregional PENK-A 119–159 and N-terminal protachykinin A (PTA) were assessed by a newly developed chemoluminescence sandwich immunoassay, using a chemiluminescence platform and coated tube technique (Immunochemical Intelligence GmbH; Berlin, Germany).
Of 189 patients assessed, 65.6% presented with a stroke, 8.5% with a TIA, and 25.9% with a nonischemic event. The normal range of PENK-A is 41.8 to 131 pmol/L, and for PTA, the normal range is 30.8 to 179.2 pmol/L. The median level of PENK-A for the stroke patients was 123.8 pmol/L (range 93 - 160.5 pmol/L), while for TIA patients the median level was TIA 114.5 pmol/L (range 85.3 - 138.8 pmol/L). All the nonischemic event patients had PENK-A levels below 137.6 pmol/L. The PENK-A concentration increased in parallel to increasing severity of stroke. The PENK-A levels on admission in the 24 patients who subsequently died were significantly elevated compared to those of survivors.
Wolfram Doehner, MD, PhD, the senior author of the study, said, "Our data are intriguing and may help to advance the use of biomarkers in the clinical evaluation of stroke patients. There is clearly an unmet need to establish biomarker-guided prognostic and functional evaluations for patients with stroke. Unfortunately, we are severely running behind in the use of biomarkers for stroke evaluation compared to acute cardiac events." The study was published on July 16 2012 in the Journal of the American College of Cardiology.
Related Links:
Center for Stroke Research
Immunochemical Intelligence GmbH
Plasma concentrations of precursor fragments of the neuropeptide enkephalin (proenkephalin A, or PENK-A) are elevated in patients with acute stroke, and are correlated with stroke severity and with brain lesion size, and they predicted mortality and more severe functional disability.
Scientists at the Center for Stroke Research (Berlin, Germany) measured plasma PENK-A and protachykinin A (PTA) concentrations in 189 consecutive patients who were admitted to hospital with symptoms of acute stroke. Midregional PENK-A 119–159 and N-terminal protachykinin A (PTA) were assessed by a newly developed chemoluminescence sandwich immunoassay, using a chemiluminescence platform and coated tube technique (Immunochemical Intelligence GmbH; Berlin, Germany).
Of 189 patients assessed, 65.6% presented with a stroke, 8.5% with a TIA, and 25.9% with a nonischemic event. The normal range of PENK-A is 41.8 to 131 pmol/L, and for PTA, the normal range is 30.8 to 179.2 pmol/L. The median level of PENK-A for the stroke patients was 123.8 pmol/L (range 93 - 160.5 pmol/L), while for TIA patients the median level was TIA 114.5 pmol/L (range 85.3 - 138.8 pmol/L). All the nonischemic event patients had PENK-A levels below 137.6 pmol/L. The PENK-A concentration increased in parallel to increasing severity of stroke. The PENK-A levels on admission in the 24 patients who subsequently died were significantly elevated compared to those of survivors.
Wolfram Doehner, MD, PhD, the senior author of the study, said, "Our data are intriguing and may help to advance the use of biomarkers in the clinical evaluation of stroke patients. There is clearly an unmet need to establish biomarker-guided prognostic and functional evaluations for patients with stroke. Unfortunately, we are severely running behind in the use of biomarkers for stroke evaluation compared to acute cardiac events." The study was published on July 16 2012 in the Journal of the American College of Cardiology.
Related Links:
Center for Stroke Research
Immunochemical Intelligence GmbH
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Biological Indicator Vials
BI-O.K.
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Pathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read more
Industry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more
